Predict your next investment

Private Equity
greensandsequity.com

See what CB Insights has to offer

Investments

2

About Green Sands Equity

Green Sands Equity is a boutique private equity investment and corporate finance advisory firm, headquartered in San Francisco.

Green Sands Equity Headquarter Location

220 Montgomery Street Suite 468

San Francisco, California, 94104,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Green Sands Equity News

ReViral Raises $44M in Series C Financing

Aug 27, 2020

ReViral Ltd. , a Stevenage, UK and Durham, NC-based clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), closed a US $44m Series C financing. The round was led by CR-CP Life Science Fund with participation from Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. In conjunction with the funding, Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joined the ReViral Board of Directors. The company intends to use the funds to conduct Phase 2 clinical development for sisunatovir, its wholly-owned fusion protein inhibitor, and to progress its N-protein replication inhibitor program into Phase 1. Led by Alex Sapir, CEO, ReViral is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics, with an initial focus on the treatment of respiratory syncytial virus (RSV). The company’s lead product candidate, sisunatovir, is an orally administered fusion inhibitor currently being evaluated in two global Phase 2 clinical studies: one in a pediatric patient population and the other in an adult stem-cell transplant patient population. In addition, the company has an N-protein replication inhibitor program in late preclinical development. Both programs were discovered in-house and the company has retained worldwide development and commercialization rights. FinSMEs 27/08/2020

Green Sands Equity Investments

2 Investments

Green Sands Equity has made 2 investments. Their latest investment was in ReViral as part of their Series C on August 8, 2020.

CBI Logo

Green Sands Equity Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/25/2020

Series C

ReViral

$44M

Yes

4

Other Investors

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/25/2020

Round

Series C

Other Investors

Company

ReViral

Subscribe to see more

Amount

$44M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

4

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.